The activation of the NF-κB pathway through progesterone-dependent RANK/RANKL signaling leads to breast tissue proliferation [14–16], as well as the induction of BC [17, 18], while genetic and pharmacological RANK inhibition evidently reduce the likelihood of tumor formation [13]. The gene discussed is TNFSF11; the disease is breast cancer.